These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19304324)

  • 1. Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
    Hussein K; Tefferi A
    Leuk Res; 2009 Aug; 33(8):e132-3. PubMed ID: 19304324
    [No Abstract]   [Full Text] [Related]  

  • 2. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
    Peñarrubia MJ; Silvestre LA; Conde J; Cantalapiedra A; Garcia Frade LJ
    Leuk Res; 2009 Jun; 33(6):e8-9. PubMed ID: 19168219
    [No Abstract]   [Full Text] [Related]  

  • 3. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
    Sekeres MA; Gundacker H; Lancet J; Advani A; Petersdorf S; Liesveld J; Mulford D; Norwood T; Willman CL; Appelbaum FR; List AF
    Blood; 2011 Jul; 118(3):523-8. PubMed ID: 21551228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
    Adès L; Eclache V; Gardin C; Boehrer S; Leroux G; Martiat P; Fenaux P
    Bone Marrow Transplant; 2010 Apr; 45(4):791-2. PubMed ID: 19718061
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
    Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
    Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
    [No Abstract]   [Full Text] [Related]  

  • 7. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
    Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
    Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
    [No Abstract]   [Full Text] [Related]  

  • 8. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
    Ford CD; Asch J; Konopa K; Petersen FB
    Bone Marrow Transplant; 2010 Feb; 45(2):403-4. PubMed ID: 19597424
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Arcioni F; Roncadori A; Di Battista V; Tura S; Covezzoli A; Cundari S; Mecucci C;
    Eur J Haematol; 2018 Jul; 101(1):78-85. PubMed ID: 29569278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA
    Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
    Lancet JE; List AF; Moscinski LC
    Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
    [No Abstract]   [Full Text] [Related]  

  • 12. Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
    Basile FG
    Leuk Lymphoma; 2009 Apr; 50(4):653-5. PubMed ID: 19373666
    [No Abstract]   [Full Text] [Related]  

  • 13. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
    Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
    Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the
    Ades L; Prebet T; Stamatoullas A; Recher C; Guieze R; Raffoux E; Bouabdallah K; Hunault M; Wattel E; Stalnikiewicz L; Toma A; Dombret H; Vey N; Sebert M; Gardin C; Chaffaut C; Chevret S; Fenaux P
    Haematologica; 2017 Apr; 102(4):728-735. PubMed ID: 28034993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 19. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.
    Scharenberg C; Jansson M; Saft L; Hellström-Lindberg E
    Br J Haematol; 2018 Feb; 180(4):526-533. PubMed ID: 29377069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.